Eli Lilly’s most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $115.00 short put and a strike $110.00 long put offers a potential 11.86% return on risk over the next 15 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $115.00 by expiration. The full premium credit of $0.53 would be kept by the premium seller. The risk of $4.47 would be incurred if the stock dropped below the $110.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 59.53 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
Tue, 04 Dec 2018 22:25:10 +0000
Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
Ajovy Is a New Growth Driver for Teva Pharmaceutical
Tue, 04 Dec 2018 14:02:05 +0000
How Is Teva Pharmaceutical Positioned in 2018? On September 14, Teva Pharmaceutical (TEVA) issued a press release announcing FDA approval of Ajovy, a humanized monoclonal antibody and anti-calcitonin gene-related peptide (or CGRP) therapy for migraine prevention indication. Teva Pharmaceutical expects to secure regulatory approval from the European Commission (or EC) for Ajovy in migraine prevention indication in H1 2019.
Bayer Is Just the Latest Pharma Giant to Get Back to Basics
Tue, 04 Dec 2018 12:00:00 +0000
With the announced sale of its animal health division, Bayer became the latest pharmaceutical company to reverse this decade-long M&A binge.
3 Big Pharma Stocks Hitting 52-Week Highs — Are They Buys?
Tue, 04 Dec 2018 11:00:00 +0000
Could big wins for these big pharma stocks in 2018 translate to more big returns?
NCCN Oncology Research Program Awarded $2 Million from Lilly to Study Mechanisms of Resistance to CDK4 & 6 Inhibitors in Breast Cancer Treatment
Mon, 03 Dec 2018 15:15:00 +0000
Project to focus on preclinical and clinical research with cyclin dependent kinase (CDK)4 & 6 inhibitors PLYMOUTH MEETING, Pa. and INDIANAPOLIS , Dec. 3, 2018 /PRNewswire/ — The National Comprehensive …
Also on Market Tamer…
Follow Us on Facebook